Breaking News Instant updates and real-time market news.

FAST

Fastenal

$49.53

-0.08 (-0.16%)

, WDFC

WD-40

$153.15

1.9 (1.26%)

19:00
07/10/18
07/10
19:00
07/10/18
19:00

On The Fly: After Hours Movers

HIGHER: Fastenal (FAST) up 2.0% after raising dividend. DOWN AFTER EARNINGS: WD-40 Company (WDFC) down 2.7%. ALSO LOWER: Idera Pharmaceuticals (IDRA) down 8.0% after terminating merger agreement with Biocryst (BCRX), up 2.9%... Natera (NTRA) down 5.9% after equity offering... Sempra Investment (SAR) down 3.2%... Sempra Energy (SRE) down 2.7% after equity offering... Twitter (TWTR) down 1.2% after being initiated at Reduce at Nomura... AT&T (T) down 0.7% after being initiated at Underperform at Credit Suisse.

FAST

Fastenal

$49.53

-0.08 (-0.16%)

WDFC

WD-40

$153.15

1.9 (1.26%)

IDRA

Idera Pharmaceuticals

$1.38

-0.01 (-0.72%)

BCRX

BioCryst

$6.15

(0.00%)

NTRA

Natera

$21.03

1.22 (6.16%)

SAR

Saratoga Investment

$27.00

-0.01 (-0.04%)

SRE

Sempra Energy

$117.29

1.59 (1.37%)

TWTR

Twitter

$43.74

-0.39 (-0.88%)

T

AT&T

$32.50

0.34 (1.06%)

  • 10

    Jul

  • 10

    Jul

  • 10

    Jul

  • 11

    Jul

  • 11

    Jul

  • 11

    Jul

  • 17

    Jul

  • 23

    Jul

  • 24

    Jul

  • 27

    Jul

  • 11

    Jul

  • 11

    Jul

  • 12

    Jul

FAST Fastenal
$49.53

-0.08 (-0.16%)

07/03/18
BARD
07/03/18
DOWNGRADE
BARD
Neutral
Fastenal downgraded to Neutral from Outperform at Baird
07/03/18
BARD
07/03/18
DOWNGRADE
BARD
Baird downgrades industrial and building distributors as cyclical risks rise
As previously reported, Baird analyst David Manthey downgraded several industrial supply distributors and building products distributors based on elevated later-cycle risks. The analyst thinks the cycle and individual company results could remain solid for quarters or years to come, but he believes the cycle is in its later stages, thereby elevating risks to gross margins, rising labor costs, and earnings deceleration in 2019. Manthey downgraded Watsco (WSO), SiteOne Landscape (SITE), Pool (POOL), Fastenal (FAST), BMC Stock Holdings (BMCH), Grainger (GWW) and GMS (GMS), all to Neutral from Outperform. He lowered his price target on Grainger to $318 from $327 and also lowered his price target on Beacon Roofing (BECN) to $59 from $68. However, Manthey said Beacon, on which he kept an Outperform rating, remains a Fresh Pick and his top tactical idea.
07/03/18
07/03/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. United Continental (UAL), American Airlines (AAL), and Delta Airlines (DAL) downgraded to Hold from Buy at Deutsche Bank with analyst Michael Linenberg saying in a world of "heightened" macroeconomic and geopolitical risks, economically-sensitive, high beta stocks such as airlines typically underperform the broader market. 2. Belmond (BEL) downgraded to Underweight from Overweight at Barclays with analyst Felicia Hendrix citing an analysis of the company's progress on its growth targets announced back in June 2016. 3. PSEG (PEG) downgraded to Hold from Buy at Deutsche Bank with analyst Jonathan Arnold saying The Federal Energy Regulatory Commission order raised new questions over New Jersey zero-emission credits. 4. PepsiCo (PEP) downgraded to Hold from Buy at Deutsche Bank with analyst Stephen Powers viewing the current valuation as a "bit bubbly." 5. Watsco (WSO), Fastenal (FAST), and Grainger (GWW) downgraded to Neutral from Outperform at Baird with analyst David Manthey saying he thinks the cycle and individual company results could remain solid for quarters or years to come, but he believes the cycle is in its later stages, thereby elevating risks to gross margins, rising labor costs, and earnings deceleration in 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/06/18
BMOC
07/06/18
NO CHANGE
Target $54
BMOC
Market Perform
Fastenal price target lowered to $54 from $57 at BMO Capital
BMO Capital analyst R. Scott Graham lowered his price target on Fastenal to $54 and kept his Market Perform rating as part of his broader research note previewing Q2 earnings for Industrial Distribution stocks. Graham notes that while he does not see a slowdown in sales or any indications of forthcoming weakness in short cycle for the group, his price target revision is driven by a "reduced relative to peers multiple assumption" because of the company's Q1 pricing trends and lack of leverage.
WDFC WD-40
$153.15

1.9 (1.26%)

IDRA Idera Pharmaceuticals
$1.38

-0.01 (-0.72%)

06/13/18
JMPS
06/13/18
NO CHANGE
Target $4
JMPS
Outperform
Idera Pharmaceuticals price target lowered to $4 from $8 at JMP Securities
JMP Securities analyst Konstantinos Aprilakis lowered his price target on Idera Pharmaceuticals to $4 from $8 after the company's Phase 2 trial of IMO-8400 in the dermatomyositis setting did not meet its primary endpoint. While he views this latest development for IMO-8400 as disappointing, he reminds investors of the positive tilsotolimod data recently presented at ASCO and still thinks tilsotolimod plus ipilimumab has the potential for a favorable competitive profile in the anti PD-1 refractory melanoma setting. Aprilakis keeps an Outperform rating on Idera shares.
11/09/17
PIPR
11/09/17
NO CHANGE
Target $4
PIPR
Overweight
Piper reiterates Overweight rating on Idera after IMO-2125 trial update
After Idera Pharmaceuticals reported a 5th unconfirmed RECIST response in its ongoing IMO-2125 plus Yervoy combo trial in PD-1 refractory metastatic melanoma, bringing the ORR to 50%, Piper Jaffray analyst Edward Tenthoff reiterated his Overweight rating and $4 price target on the stock, which is up 15% to $2.03 in midday trading.
11/09/17
11/09/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AnaptysBio (ANAB) initiated with a Buy at Jefferies. 2. Regenxbio (RGNX) resumed with an Overweight at Morgan Stanley. 3. GTx (GTXI) initiated with a Buy at Stifel. 4. Idera Pharmaceuticals (IDRA) initiated with a Buy at H.C. Wainwright. 5. Nektar (NKTR) initiated with a Buy at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/17
HCWC
11/09/17
INITIATION
Target $4
HCWC
Buy
Idera Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth started Idera Pharmaceuticals with a Buy rating and $4 price target. The company's two lead products have "significant potential in the fast growing immunotherapy market," the analyst contends.
BCRX BioCryst
$6.15

(0.00%)

06/22/18
06/22/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sunlands Online (STG) initiated with an Outperform at Credit Suisse. 2. Micron (MU) initiated with a Buy at Benchmark. 3. Interpace Diagnostics (IDXG) initiated with a Buy at Ladenburg. 4. Alteryx (AYX) initiated with an Outperform at Oppenheimer. 5. BioCryst (BCRX) initiated with a Neutral at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/22/18
GHSC
06/22/18
INITIATION
GHSC
Neutral
BioCryst initiated with a Neutral at Seaport Global
Seaport Global initiated BioCryst (BCRX) with a Neutral due to uncertainty on its proposed merger with Idera Pharmaceuticals (IDRA) and views risk/reward as balanced.
01/02/18
RBCM
01/02/18
UPGRADE
Target $8
RBCM
Outperform
BioCryst upgraded to Outperform at RBC Capital on BCX7353 performance
As reported earlier, RBC Capital analyst Brian Abrahams upgraded BioCryst to Outperform from Sector Perform and raised his price target to $8 from $6. Abrahams says the lead drug BCX7353 showed a clear reduction in hereditary angioedema attacks in its phase 2 study, while its lack of dose dependence is "legitimately explainable by misidentification of GI side effects at the higher doses". The analyst adds that the recent FDA precedent also implies a "relatively low bar for approvals of drugs to treat rare, potentially fatal diseases".
01/02/18
RBCM
01/02/18
UPGRADE
RBCM
Outperform
BioCryst upgraded to Outperform from Sector Perform at RBC Capital
NTRA Natera
$21.03

1.22 (6.16%)

06/28/18
BARD
06/28/18
NO CHANGE
Target $20
BARD
Outperform
Natera remains a top small-cap pick following update, says Baird
Baird analyst Catherine Ramsey Schulte said Natera remains a top small-cap pick following its pipeline update. The analyst believes there will likely be numerous partnership announcements over the next 6-12 months and thinks the pipeline remains undervalued. Schulte reiterated her Outperform rating and raised her price target to $20 from $17 on Natera shares.
06/28/18
ADAM
06/28/18
NO CHANGE
Target $22
ADAM
Buy
Natera pipeline call outlined path to large business segments, says Canaccord
Canaccord analyst Mark Massaro said Natera's pipeline call outlined a path to large business segments and he felt it provided visibility on its plans for oncology and organ transplant rejection development. He said he remains an aggressive buyer of the shares as the company is sitting on a number of catalysts. Massaro reiterated his Buy rating and raised his price target to $22 from $20 on Natera shares.
06/28/18
CHLM
06/28/18
NO CHANGE
Target $23
CHLM
Buy
Natera price target raised to $23 from $16 at Craig-Hallum
Craig-Hallum analyst Alexander Nowak raised his price target for Natera to $23 from $16 as he remains positive following its transplant and oncology update call. After speaking with management, the analyst is more comfortable on the reimbursement pathway as well as commercialization. Nowak reiterates a Buy rating on the shares as he sees multiple upside drivers pushing the stock higher.
07/05/18
PIPR
07/05/18
NO CHANGE
Target $21
PIPR
Overweight
Natera price target raised to $21 from $18 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Natera to $21 after Dr. Sarwal presented on the company's dd-cfDNA test for monitoring kidney health at the TTS meeting in Madrid. Dr. Sarwal reiterated the data released last week and noted that Natera's assay can be used logituditally, like AlloSure, which is expected, Quirk tells investors in a research note. Disappointingly, Dr. Sarwal was not certain what the AUC for creatinine was in the broader cohort, the analyst adds. He continues to believe Natera has "material opportunity" in transplant, but that CareDx (CDNA) has a "significant head start in a concentrated market." Quirk keeps an Overweight rating on Natera.
SAR Saratoga Investment
$27.00

-0.01 (-0.04%)

10/17/17
MAXM
10/17/17
NO CHANGE
Target $24
MAXM
Buy
Saratoga Investment price target raised to $24 from $23 at Maxim
Maxim analyst Michael Diana raised his price target on Saratoga Investment to $24 and kept his Buy rating following Q2 results. Diana attributes the increase to the 3.1% NAV increase and says Saratoga deserves a premium valuation in spite of higher leverage because of its strong credit quality record and lower-risk loan strategies.
03/27/18
RILY
03/27/18
INITIATION
Target $23.5
RILY
Buy
Saratoga Investment initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Tim Hayes started Saratoga Investment with a Buy rating and $23.50 price target. The analyst believes the company offers a "strong dividend growth story."
05/29/18
COMP
05/29/18
DOWNGRADE
COMP
Neutral
Saratoga Investment downgraded to Neutral from Buy at Compass Point
05/29/18
05/29/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Novartis (NVS) downgraded to Hold from Buy at HSBC. 2. Nokia (NOK) downgraded to Hold from Buy at Nordea. 3. Infinera (INFN) downgraded to Underperform from Hold at Jefferies with analyst George Notter saying he believes the upside case is fairly reflected at current valuation levels while the company's innovation lagging peers. 4. Saratoga Investment (SAR) downgraded to Neutral from Buy at Compass Point. 5. Nanometrics (NANO) downgraded to Hold from Buy at Stifel with analyst Patrick Ho citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SRE Sempra Energy
$117.29

1.59 (1.37%)

07/09/18
ARGS
07/09/18
NO CHANGE
Target $130
ARGS
Buy
Sempra Energy price target raised to $130 from $119 at Argus
Argus analyst Jacob Kilstein raised his price target on Sempra Energy to $130 and kept his Buy rating, citing the management's favorable guidance at its June 28th invest meeting. The analyst is also positive on the efforts made by activist investors Elliott Management and Bluescape Resources to increase profitability as they push for Sempra Energy to sells its international businesses and separate the company into a utility-focused entity and a natural gas infrastructure one. Kilstein further points to the management's estimates of the purchased Oncor majority stake to increase earnings by 10c-20c over the next four years.
06/12/18
06/12/18
DOWNGRADE
Target $123

Market Perform
Sempra Energy downgraded to Market Perform at Wells Fargo
As previously reported, Wells Fargo analyst Sarah Akers downgraded Sempra Energy to Market Perform from Outperform, citing balanced risk/reward following activist-driven pop. While the analyst sees opportunities to unlock value via effective capital allocation and new growth ventures, she would not argue for multiple expansion at this point given below average credit metrics and ongoing risks. Akers also raised her price target on the stock to $123 from $118.
06/12/18
WELS
06/12/18
DOWNGRADE
WELS
Market Perform
Sempra Energy downgraded to Market Perform from Outperform at Wells Fargo
05/21/18
05/21/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Snap (SNAP) upgraded to Neutral from Sell at MoffettNathanson. 2. ProsHoldings (PROS) upgraded to Outperform from Market Perform at Northland with analyst Tim Klasell citing last week's annual user conference and analyst meetings. 3. Ctrip (CTRP) upgraded to Buy from Hold at TH Data Capital with analyst Tian Hou saying the company's business has "already stabilized and is on its way to recovery." 4. Sempra Energy (SRE) upgraded to Buy from Hold at Argus with analyst Jacob Kilstein citing anticipated earnings accretion from the recent purchase of a majority stake in Oncor, favorable regulations, and the growing base rate at its California utilities. 5. Dillard's (DDS) upgraded to Buy from Underperform at BofA/Merrill with analyst Heather Balsky saying she expects improved consumer sentiment, especially in the energy market, to support positive comps and drive multiple expansion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TWTR Twitter
$43.74

-0.39 (-0.88%)

07/10/18
NOMU
07/10/18
INITIATION
Target $31
NOMU
Reduce
Twitter initiated with a Reduce at Nomura Instinet
Nomura initiated Twitter with a Reduce and $31 price target.
07/10/18
NOMU
07/10/18
INITIATION
NOMU
Nomura Instinet initiates coverage on Americas Internet
Nomura Instinet initiated coverage on nine names within the Americas Internet sector. The firm believes, overall, that there is "still some room for growth in digital advertising for the foreseeable future" and believes it will be led primarily by digital video and social, and primarily on mobile devices. The firm added that, as a result of slowing user growth and already high internet penetration, the growth will likely be led by pricing, rather than volume, and the consistent shift away from offline to online media. Nomura Instinet forecast the global digital advertising market "will grow at a 15% five-year CAGR through 2020 as digital ads work toward constituting half of total advertising spend," which the firm expects to occur in 2020. Nomura Instinet initiated Alphabet Class A (GOOGL), Facebook (FB), and Spotify (SPOT) with Buy ratings, and added that Alphabet and Facebook were the best positioned in this newly regulated industry. It initiated Netflix (NFLX), Snap (SNAP), Trade Desk (TTD), Criteo (CRTO), and Pandora (P) with Neutral ratings. It initiated Twitter (TWTR) with a Reduce rating, saying that while it is a "stable long-term asset that has something for everyone," the firm believes the market is pricing in "a significant advertising reacceleration that implies a shift in ad spend," while the firm expects "stability instead of a reacceleration of growth."
07/10/18
07/10/18
INITIATION
Target $31

Reduce
Nomura Instinet starts Twitter with Reduce rating, $31 price target
As previously reported, Nomura Instinet initiated Twitter with a Reduce rating and $31 price target, stating that they view it as a unique platform, but also believe the market is pricing in a significant advertising reacceleration that implies a shift in ad spending. The firm does not expect a reacceleration of growth, but rather stability.
07/10/18
CLVD
07/10/18
INITIATION
Target $46
CLVD
Neutral
Twitter assumed with a Neutral at Cleveland Research
Cleveland Research analyst Chandler Converse reinstated Twitter with a Neutral and $46 price target saying he is modeling CY19 above consensus on improved ad spend trends and CY19 slightly below due to concerns regarding long-term competitiveness in streaming/content.
T AT&T
$32.50

0.34 (1.06%)

06/26/18
CHLM
06/26/18
NO CHANGE
Target $4
CHLM
Buy
Rubicon Project to benefit from AT&T acquisition of AppNexus, says Craig-Hallum
Craig-Hallum analyst Jason Kreyer notes that AT&T (T) announced the acquisition of AppNexus, a deal rumored to be valued at $1.6B. The analyst sees this deal having a ripple effect through the ad tech landscape, particularly as it relates to the publisher's end of the spectrum. In his view, Rubicon Project (RUBI) stands to benefit substantially by the removal of an aggressive competitor, with thousands of publishers and hundreds of millions of advertising spend likely searching for a new home. Further, Kreyer now sees the integration of AppNexus under the AT&T umbrella as the number one growth catalyst for Rubicon over the next 12-18 months as a substantial volume of ad impressions likely search for a new home. He reiterates a Buy rating and $4 price target on Rubicon's shares.
07/10/18
FBCO
07/10/18
INITIATION
Target $29
FBCO
Underperform
AT&T initiated with an Underperform at Credit Suisse
As reported earlier, Credit Suisse analyst Douglas Mitchelson initiated AT&T with an Underperform rating and a price target of $29. The analyst notes that the company has become the first large communications entity to bring leading businesses in connectivity, pay TV and media together, but the outlook for wireline and pay video looks "very challenged". Mitchelson adds that AT&T will require greater scale and a shift to global direct-to-consumer distribution, stating that the elevated execution risk under its ownership structure and its wireless business look mature with little chance for stabilization in spite of the coming 5G technology.
07/10/18
FBCO
07/10/18
INITIATION
Target $29
FBCO
Underperform
AT&T initiated with an Underperform at Credit Suisse
Credit Suisse initiated AT&T an Underperform and $29 price target.
06/27/18
MSCO
06/27/18
UPGRADE
Target $37
MSCO
Overweight
AT&T resumed at Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Simon Flannery resumed coverage of AT&T with an Overweight rating and $37 price target. The firm had previously had an Equal Weight rating on the stock prior to moving to restricted in its coverage. He also upgraded his view of the Telecom Services industry to In-Line from Cautious, stating that while he maintains some of his longer term concerns around the sector and the stock, he believes that over the next 12 months, the path of least resistance for AT&T's stock is to trade higher given that it is currently trading "well below" historical valuation levels.

TODAY'S FREE FLY STORIES

TALO

Talos Energy

$29.85

-1.49 (-4.75%)

18:05
10/17/18
10/17
18:05
10/17/18
18:05
Hot Stocks
Talos Energy reaches pact with Hokchi to cross-assign interests »

Talos Energy Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

STLD

Steel Dynamics

$40.55

0.29 (0.72%)

18:05
10/17/18
10/17
18:05
10/17/18
18:05
Hot Stocks
Steel Dynamics CEO says 'delivered a tremendous third quarter performance' »

"The team delivered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

STLD

Steel Dynamics

$40.55

0.29 (0.72%)

18:02
10/17/18
10/17
18:02
10/17/18
18:02
Hot Stocks
Steel Dynamics CEO: We believe steel consumption will continue to be strong »

"We remain confident…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

STLD

Steel Dynamics

$40.55

0.29 (0.72%)

18:01
10/17/18
10/17
18:01
10/17/18
18:01
Earnings
Steel Dynamics reports Q3 adjusted EPS $1.69, consensus $1.64 »

Reports Q3 revenue $3.2B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

CRTO

Criteo

$23.00

-0.29 (-1.25%)

, RUBI

Rubicon Project

$3.77

-0.06 (-1.57%)

17:44
10/17/18
10/17
17:44
10/17/18
17:44
Periodicals
Advertising technology firm DataXu exploring sale, WSJ says »

DataXu, which offers…

CRTO

Criteo

$23.00

-0.29 (-1.25%)

RUBI

Rubicon Project

$3.77

-0.06 (-1.57%)

FUEL

Rocket Fuel

$0.00

(0.00%)

GOOG

Alphabet

$1,115.99

-4.12 (-0.37%)

FB

Facebook

$159.46

0.65 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

  • 07

    Nov

  • 15

    Nov

  • 16

    Nov

  • 03

    Mar

BTU

Peabody Energy

$36.09

-0.31 (-0.85%)

17:37
10/17/18
10/17
17:37
10/17/18
17:37
Hot Stocks
Peabody Energy increases quarterly dividend nearly 4% to 13c per share »

Peabody Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDN

Brandywine Realty

$14.56

-0.11 (-0.75%)

17:34
10/17/18
10/17
17:34
10/17/18
17:34
Earnings
Brandywine Realty sees FY19 FFO $1.37-$1.47, consensus $1.44 »

Sees FY17 EPS 36c-46c,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.56

-0.11 (-0.75%)

17:33
10/17/18
10/17
17:33
10/17/18
17:33
Earnings
Brandywine Realty narrows FY18 FFO view to $1.36-$1.40 from $1.35-$1.41 »

Consensus for FY18 FFO is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.56

-0.11 (-0.75%)

17:32
10/17/18
10/17
17:32
10/17/18
17:32
Earnings
Brandywine Realty reports Q3 FFO 35c, consensus 35c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BPRN

Bank of Princeton

$30.75

-0.16 (-0.52%)

17:32
10/17/18
10/17
17:32
10/17/18
17:32
Hot Stocks
Bank of Princeton declares initial cash dividend of 3c per share »

This dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBAY

eBay

$32.01

-0.25 (-0.77%)

, AMZN

Amazon.com

$1,832.81

14.81 (0.81%)

17:26
10/17/18
10/17
17:26
10/17/18
17:26
Periodicals
eBay sues Amazon, claims sellers were illegally poached, WSJ says »

eBay (EBAY) has filed a…

EBAY

eBay

$32.01

-0.25 (-0.77%)

AMZN

Amazon.com

$1,832.81

14.81 (0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 25

    Oct

  • 30

    Oct

  • 03

    Mar

OIS

Oil States

$29.77

-0.13 (-0.43%)

17:18
10/17/18
10/17
17:18
10/17/18
17:18
Earnings
Oil States sees Q3 revenue at low end of $273M-$298M, consensus $288.81M »

Oil States announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$45.90

-0.03 (-0.07%)

17:15
10/17/18
10/17
17:15
10/17/18
17:15
Periodicals
Intel 'shakes up' manufacturing unit amid production missteps, Oregonian says »

Sohail Ahmed, who has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

NOC

Northrop Grumman

$309.25

-2.87 (-0.92%)

17:15
10/17/18
10/17
17:15
10/17/18
17:15
Hot Stocks
Northrop Grumman awarded $697.03M Navy contract »

Northrop Grumman doing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 30

    Oct

CCK

Crown Holdings

$47.64

-0.25 (-0.52%)

17:14
10/17/18
10/17
17:14
10/17/18
17:14
Hot Stocks
Crown Holdings CEO says Q3 performance 'solid' »

Commenting on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

PETQ

PetIQ

$34.46

-1.17 (-3.28%)

17:13
10/17/18
10/17
17:13
10/17/18
17:13
Hot Stocks
PetIQ announces strategic acquisition of HBH Enterprises »

PetIQ announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCK

Crown Holdings

$47.64

-0.25 (-0.52%)

17:10
10/17/18
10/17
17:10
10/17/18
17:10
Hot Stocks
Crown Holdings sees FY18 adjusted free cash flow approximately $625M »

Sees FY19 adjusted free…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

ZS

Zscaler

$37.95

-1.11 (-2.84%)

17:09
10/17/18
10/17
17:09
10/17/18
17:09
Initiation
Zscaler initiated  »

Zscaler assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 10

    Dec

CCK

Crown Holdings

$47.64

-0.25 (-0.52%)

17:08
10/17/18
10/17
17:08
10/17/18
17:08
Hot Stocks
Breaking Hot Stocks news story on Crown Holdings »

Crown Holdings sees FY18…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

CCK

Crown Holdings

$47.64

-0.25 (-0.52%)

17:08
10/17/18
10/17
17:08
10/17/18
17:08
Earnings
Breaking Earnings news story on Crown Holdings »

Crown Holdings sees Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

SYMC

Symantec

$20.57

-0.085 (-0.41%)

17:07
10/17/18
10/17
17:07
10/17/18
17:07
Initiation
Symantec initiated  »

Symantec assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Dec

CCK

Crown Holdings

$47.64

-0.25 (-0.52%)

17:07
10/17/18
10/17
17:07
10/17/18
17:07
Hot Stocks
Breaking Hot Stocks news story on Crown Holdings »

Crown Holdings says Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

SPY

SPDR S&P 500 ETF Trust

$280.41

0.18 (0.06%)

, SPX

S&P 500

$0.00

(0.00%)

17:07
10/17/18
10/17
17:07
10/17/18
17:07
General news
U.S. Treasury: China continues to warrant placement on Monitoring List »

Says: "United States…

SPY

SPDR S&P 500 ETF Trust

$280.41

0.18 (0.06%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCK

Crown Holdings

$47.64

-0.25 (-0.52%)

17:06
10/17/18
10/17
17:06
10/17/18
17:06
Earnings
Crown Holdings reports Q3 adjusted EPS $1.71, consensus $1.65 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

RHT

Red Hat

$124.83

-0.71 (-0.57%)

17:06
10/17/18
10/17
17:06
10/17/18
17:06
Initiation
Red Hat initiated  »

Red Hat assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 30

    Oct

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.